clinical trial · NCT05206370
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
Achieve Life Sciences·phase3·completed·n = 792
Smoking CessationCytisiniclinePlaceboBehavioral support
brief summary
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
started
Jan 20, 2022
primary completion
Mar 21, 2023
completion
Mar 21, 2023
last updated
Jan 14, 2026
official title
A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol